Article

Analysis of Chromosome 1p Abnormalities in Renal Oncocytomas by Loss of Heterozygosity Studies Correlation With Conventional Cytogenetics and Fluorescence In Situ Hybridization

Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA.
American Journal of Clinical Pathology (Impact Factor: 3.01). 04/2008; 129(3):377-82. DOI: 10.1309/KC2465ANDWVAXYDM
Source: PubMed

ABSTRACT We previously showed by cytogenetics and fluorescence in situ hybridization (FISH) that the most common chromosomal abnormality in renal oncocytomas is loss of chromosome 1 or 1p. In the present study, we evaluated chromosome 1 by loss of heterozygosity (LOH) studies. DNA was extracted from paraffin sections. Three microsatellite markers were used: D1S508, D1S199, and D1S2734. The regions targeted by FISH probes and LOH markers were close to each other but not overlapping. Among 16 tumors evaluated by all 3 techniques, in 2 cases, LOH could not be interpreted. LOH was detected in at least 1 locus in 12 (86%) of 14 renal oncocytomas studied, with other loci being noninformative or not interpretable (1 case). In 2 cases, the LOH results were inconclusive. These results provide further evidence to support widespread abnormalities in chromosome 1p in renal oncocytoma. Determining whether such abnormalities are unique to renal oncocytomas or are also present in other tumors requires further studies.

Download full-text

Full-text

Available from: Maria M Picken, Aug 04, 2015
0 Followers
 · 
94 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the usefulness of interphase fluorescence in situ hybridization (FISH) analysis to differentiate between 11 chromophobe renal carcinomas and 12 renal oncocytomas, showing different clinical outcomes, when compared with conventional metaphase cytogenetics by karyotyping. Karyotypically, 3 chromophobe renal cell carcinomas showed losses of chromosomes, 3 were polyploid, 1 was normal, and 4 failed to grow. Of 12 oncocytomas, 5 showed a normal numeric karyotype and 6 additional structural rearrangements. FISH on chromophobe renal cell carcinomas showed a high percentage of cases (10/11 [91%]) with multiple numeric losses among chromosomes 1, 2, 6, 10, and 17; this interphase pattern was observed irrespective of the 3 different metaphase karyotypes. Of 12 oncocytomas, 11 (92%) revealed a normal numeric chromosomal status showing at least 2 chromosomes without aneusomy by interphase FISH. The study demonstrates that indeed FISH performed on formalin-fixed, paraffin-embedded tissue can provide clinically useful information more reliably than karyotyping of most of these tumors.
    American Journal of Clinical Pathology 01/2010; 133(1):116-26. DOI:10.1309/AJCPSATJTKBI6J4N · 3.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are two distinct but closely related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, oncocytoma is usually regarded as a benign entity. The overlapping characteristics are best explained by a common cellular origin, and the biologic differences between chRCC and oncocytoma are therefore of considerable interest in terms of carcinogenesis, diagnosis and clinical management. Previous studies have been relatively limited in terms of examining the differences between oncocytoma and chromophobe RCC. Gene expression profiling using the Affymetrix HGU133Plus2 platform was applied on chRCC (n = 15) and oncocytoma specimens (n = 15). Supervised analysis was applied to identify a discriminatory gene signature, as well as differentially expressed genes. High throughput single-nucleotide polymorphism (SNP) genotyping was performed on independent samples (n = 14) using Affymetrix GeneChip Mapping 100 K arrays to assess correlation between expression and gene copy number. Immunohistochemical validation was performed in an independent set of tumors. A novel 14 probe-set signature was developed to classify the tumors internally with 93% accuracy, and this was successfully validated on an external data-set with 94% accuracy. Pathway analysis highlighted clinically relevant dysregulated pathways of c-erbB2 and mammalian target of rapamycin (mTOR) signaling in chRCC, but no significant differences in p-AKT or extracellular HER2 expression was identified on immunohistochemistry. Loss of chromosome 1p, reflected in both cytogenetic and expression analysis, is common to both entities, implying this may be an early event in histogenesis. Multiple regional areas of cytogenetic alterations and corresponding expression biases differentiating the two entities were identified. Parafibromin, aquaporin 6, and synaptogyrin 3 were novel immunohistochemical markers effectively discriminating the two pathologic entities. Gene expression profiles, high-throughput SNP genotyping, and pathway analysis effectively distinguish chRCC from oncocytoma. We have generated a novel transcript predictor that is able to discriminate between the two entities accurately, and which has been validated both in an internal and an independent data-set, implying generalizability. A cytogenetic alteration, loss of chromosome 1p, common to renal oncocytoma and chRCC has been identified, providing the opportunities for identifying novel tumor suppressor genes and we have identified a series of immunohistochemical markers that are clinically useful in discriminating chRCC and oncocytoma.
    BMC Cancer 05/2010; 10:196. DOI:10.1186/1471-2407-10-196 · 3.32 Impact Factor
  • Source
    International Journal of Urology 07/2010; 17(7):613-4. DOI:10.1111/j.1442-2042.2010.02586.x · 1.80 Impact Factor
Show more